A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania

European Psychiatry

Volumn 27, Issue 4, 2012, Pages 234-239

  Perrin, E ^a   Anand, E ^a   Dyachkova, Y ^a   Wagner, T ^b   Frediani, S ^c   Ballerini, A ^d  

^a ELI LILLY AND COMPANY   (United States)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c National Mental Health Service   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Acute dystonia; Agitation; Akathisia; Bipolar mania; IM psychotropic drugs; Parkinsonism; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLONAZEPAM; CLORAZEPATE; CLOTIAPINE; DELORAZEPAM; DIAZEPAM; DROPERIDOL; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; LOXAPINE; OLANZAPINE; PROMETHAZINE; PSYCHOTROPIC AGENT; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; ASTHENIA; BIPOLAR MANIA; CLINICAL GLOBAL IMPRESSION SCALE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84860316377     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.04.005     Document Type: Article

References (21)

1. Addonizio G., Alexopoulos G.S. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988, 145:869-871.
2. Ballerini A., Boccalon R., Boncompagni G., et al. An observational study in psychiatric acute patients admitted to general hospital psychiatric wards in Italy. Ann Gen Psychiatry 2007, 6:2.
3. Ballerini A., Boccalon R.M., Boncompagni G., et al. Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (psychiatric emergency study and epidemiology) survey. Ann Gen Psychiatry 2007, 6:29.
4. Ballerini A., Boccalon R.M., Boncompagni G., et al. Main clinical features in patients at their first psychiatric admission to Italian acute hospital psychiatric wards: the PERSEO study. BMC Psychiatry 2007, 7:3.
5. Battaglia J. Pharmacological management of acute agitation. Drugs 2005, 65:1207-1222.
6. Castle D.J., Udristoiu T., Kim C.Y., Sarosi A., Pidrman V., Omar A.N., et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry 2009, 9:45-53.
7. Chandrasena R., Dvorakova D., Lee S.I., et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract 2009, 63:1249-1258.
8. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007, 68:1876-1885.
9. Currier G.W., Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006, 12:30-40.
10. Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007, 17:235-244.
11. Hartnell N.R., Wilson J.P., Patel N.C., Crismon M.L. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003, 37:1387-1391.
12. Meehan K., Zhang F., David S., et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001, 21:389-397.
13. Mohr P., Pecenak J., Svestka J., et al. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 2005, 26:327-335.
14. San L., Arranz B., Querejeta I., Barrio S., De la Gandara J., Perez V. A naturalistic multicentre study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006, 21:539-543.
15. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on exptrapyramidal function. CNS Drugs 2002, 16:23-45.
16. Taylor D. Antipsychotic prescribing - time to review practice. Psychiatr Bull 2002, 26:401-402.
17. Taylor D., Paton C., Kerwin R. The Maudsley prescribing guidelines 2009, Informa Healthcare, London, (9th Ed).
18. Thomas P., Alptekin K., Gheorghe M., Mauri M., Olivares J.M., Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009, 23:193-212.
19. Tollefson G.D., Beasley C.M., Tran P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
20. Wagstaff A.J., Easton J., Scott L.J. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 2005, 19:147-164.
21. Weiden P.J. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007, 13:13-24.